Pioneering Personalized Medicine: Lessons from Mila’s Story and a Blueprint for Scaling Bespoke Therapies

Overview

In 2018, Julia Vitarello’s daughter Mila was diagnosed with a rare, fatal genetic disease caused by a unique mutation in the MILA gene. In a landmark effort, scientists designed a custom antisense oligonucleotide (ASO) therapy tailored exactly to Mila’s DNA – a treatment created for just one patient. That therapy, milasen, extended Mila’s life and sparked a global conversation about individualized medicines. Now, eight years later, Vitarello is launching a new biotech venture aimed at scaling these bespoke therapies to help more patients.

This guide distills the journey from Mila’s single-patient treatment to a scalable biotech model. It covers the essential prerequisites, step-by-step development pathway, and common pitfalls – all based on the real-world experience of EveryONE Medicines, Vitarello’s earlier company that ultimately dissolved due to regulatory and investor challenges. Whether you’re a researcher, entrepreneur, or patient advocate, this blueprint will help you navigate the complex landscape of n-of-1 therapies and bring them to more families.

Prerequisites

Before you begin building a company to manufacture individualized therapies at scale, ensure you have the following in place:

• Deep molecular expertise: A team of geneticists, molecular biologists, and bioinformaticians who can identify pathogenic mutations and design custom therapeutics (e.g., ASOs, siRNAs, or gene-editing tools).
• Regulatory knowledge: Familiarity with FDA guidance on individualized therapies, including the latest draft released in 2023. Note that, as Vitarello discovered, the guidance may not yet fully satisfy private investors expecting a clear reimbursement or approval pathway.
• Patient community access: Partnerships with rare disease foundations and clinical networks to identify patients with unique mutations that could benefit from bespoke treatment.
• Manufacturing infrastructure: Either in-house GMP capacity or agreements with contract development organizations (CDMOs) capable of producing small batches (e.g., milligram quantities) of oligonucleotides.
• Funding runway: Initial capital that can tolerate high risk and long timelines. Vitarello’s EveryONE Medicines folded when investors hesitated due to regulatory uncertainty – so ensure your funding sources are aligned with the experimental nature of individualized medicines.

Step-by-Step Instructions

1. Identify the Right Patient-Mutation Pair

The process begins with a patient who has a confirmed, treatable genetic mutation – ideally one that can be targeted by a well-understood modality (e.g., an exon-skipping ASO). In Mila’s case, her mutation was a single-nucleotide change causing a splice defect. Your team should:

1. Sequence the patient’s genome to pinpoint the mutation.
2. Validate the mutation’s functional impact using patient-derived cells.
3. Confirm that an existing drug design platform (e.g., ASO chemistry) is applicable.
4. Establish a timeline – typically 6–12 months from diagnosis to first dose.

Example code (pseudocode for mutation filtering):

function findActionableMutation(vcfFile, genePanel) {
  let variants = parseVCF(vcfFile);
  let actionable = [];
  for (let v of variants) {
    if (genePanel.includes(v.gene) && v.pathogenicity === 'high' && v.inheritance === 'de novo') {
      actionable.push(v);
    }
  }
  return actionable;
}

2. Design the Custom Therapeutic

Work with computational chemistry and RNA biologists to design a precise therapeutic agent. For ASOs, you typically:

1. Select target region (e.g., exon-intron junction for splicing correction).
2. Run homology checks to avoid off-target effects.
3. Synthesize a 20–25 nucleotide oligonucleotide with chemical modifications (e.g., 2′-MOE) to improve stability.
4. Test in cell assays for binding affinity and functional correction.

3. Conduct Preclinical Safety and Efficacy Studies

Regulators will require at least minimal safety data. In an n-of-1 case, this often means:

• Animal toxicology (usually in mice or rats) at doses scaled to human equivalent.
• In vitro off-target prediction via RNA-seq.
• Pharmacokinetic modeling to set the starting dose for the patient.
• Documentation in an Investigator-Initiated IND or a “compassionate use” protocol.

4. Secure Regulatory Approval for Single-Patient Use

File for an individual patient IND with the FDA, or use a single-patient emergency IND if time is critical. Vitarello’s experience highlights that while the FDA has encouraged these therapies, they have not yet created a streamlined “n-of-1” pathway that satisfies investors. Your team must present a strong risk-benefit analysis and be prepared for iterative feedback.

5. Manufacture a Small Batch

Produce enough drug to cover the initial treatment course (often 3–6 months). Because the batch size is tiny, costs per milligram are high – sometimes $100,000 or more. Partner with a CDMO that specializes in small-scale GMP oligonucleotide synthesis.

6. Administer Treatment and Monitor

Administer the therapy under a strict clinical protocol. Collect efficacy endpoints (e.g., biomarker reduction, functional improvement) every 4–8 weeks. Adjust dose as needed. In Mila’s case, milasen was administered intrathecally and showed reduction in seizure frequency.

7. Build a Scalable Platform

This is the critical step where Vitarello’s new company differs from EveryONE Medicines. Rather than treating one patient at a time, you need a platform that can:

• Automate mutation identification and drug design.
• Create a library of validated ASO backbones that can be rapidly customized.
• Negotiate multi-patient IND frameworks with the FDA to lower per-patient regulatory burden.
• Attract investors by demonstrating that the platform can address a pipeline of patients with defined mutations (e.g., all patients with a specific splicing defect).

Common Mistakes

• Underestimating regulatory inertia: Relying on existing FDA guidance as sufficient to secure venture funding – Vitarello learned this firsthand. The guidance is a positive signal, but investors want a clear path to broad market approval or at least a contracted reimbursement model.
• Ignoring manufacturing costs: Custom small-batch synthesis is expensive. Without a plan to either reduce costs (e.g., modular synthesis) or secure philanthropic funding, the business model may collapse.
• Lack of patient engagement: Building a therapy for one patient without a mechanism to identify and enroll additional patients with similar mutations leads to unsustainable R&D.
• Skipping preclinical validation: Jumping directly to human dosing without reliable in vivo data can delay IND approval or cause safety issues.
• Overpromising on timelines: EveryONE Medicines struggled with investor expectations that a single-patient model would quickly scale. Be realistic: even a mature platform may take 2–3 years to treat its first 10 patients.

Summary

Julia Vitarello’s journey from Mila’s bed to the boardroom shows that individualized medicine is both scientifically feasible and commercially challenging. To succeed, you must pair cutting-edge genetic design with a flexible business model that accounts for regulatory flux. The new company Vitarello is forming aims to overcome the hurdles that sank EveryONE Medicines – by building a scalable platform, securing aligned funding, and working collaboratively with regulators. This blueprint provides the foundational steps, but each n-of-1 therapy is unique. The most important takeaway: start with the patient, but plan for the platform.